Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. S.P.C. Lam

Publicaties

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

Changes in Liver Function Tests, Congestion, and Prognosis After Acute Heart Failure: The STRONG-HF Trial

Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF

Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease

Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial

Finerenone and Outpatient Worsening Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF

Pers/media

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Wat is nieuw in de 2021 ESC HF richtlijn wat betreft patiënten met EF>40%?